Observational study of drug interactions between azvudine and tacrolimus in renal transplant recipients
OBJECTIVE To explore preliminarily the effects of azvudine(FNC)on improving clinical symptoms in coronavi-rus disease 2019(COV1D-19)renal transplant(RT)recipients and examine its impact upon drug concentration of tacrolimus(TAC)so as to provide references for the application of FNC.METHODS A retrospective analysis was conducted for 39 COVID-19 RT recipients on a treatment of FNC.Patient demographics,COVID-19 vaccination status,symptoms,co-medications and laboratory testing parameters were recorded before and after dosing.A telephone follow-up was conducted within 30 days for gathering information on COVID-19 antigen or nucleic acid test results,improvement in symptoms and changes in tacrolimus(TAC)dosage and blood drug concentration before and after medication.RESULTS During 30-day follow-ups,27 patients tested negative for nucleic acid or antigens while 10 patients were discharged without nucleic acid or antigen testing due to improved symptoms.Among 23 hospitalized patients,2 cases progressed to severe pneumonia.Among 16 outpatients,4 cases were hospitalized and 1 case progressed to severe pneumonia.Drug interaction analysis was performed in 34 patients.No signifi-cant differences existed in TAC dose,trough concentration or concentration-dose ratio before and after FNC dosing(P＞0.05).CONCLUSION A combined dosing of FNC with TAC does not impact trough concentration of the latter,thus providing pre-liminary evidence of the safety of FNC in RT recipients.However,close monitoring of gastrointestinal and hepatic injuries caused by FNC is necessary to avoid secondary changes in TAC trough concentration in clinical practices.
NETL
NSTL
万方数据
